All In Biotech

Drug Trial Radar · NCT04501978

ACTIV-3: Therapeutics for Inpatients With COVID-19

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19

Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,753 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,753

Actual

Start

Aug 4, 2020

Primary completion

Apr 6, 2022

Study completion Jul 14, 2023

Sponsor

Sponsor type
NIH
Collaborators
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Copenhagen; Medical Research Council; Kirby Institute; Washington D.C. Veterans Affairs Medical Center; Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; National Heart, Lung, and Blood Institute (NHLBI); US Department of Veterans Affairs; Prevention and Early Treatment of Acute Lung Injury; Cardiothoracic Surgical Trials Network; Eli Lilly and Company; Vir Biotechnology, Inc.; GlaxoSmithKline; Brii Biosciences Limited; AstraZeneca; Molecular Partners AG; Pfizer; University of Minnesota
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.

Conditions

  • Covid19

Interventions

  • LY3819253Biological

    Participants are no longer being randomized to this intervention.

  • PlaceboDrug

    Commercially available 0.9% sodium chloride solution. Administered by IV infusion

  • RemdesivirBiological

    Provided to all study participants as SOC unless contraindicated for an individual patient.

  • VIR-7831Biological

    Participants are no longer being randomized to this intervention.

  • BRII-196/BRII-198Biological

    Participants are no longer being randomized to this intervention.

  • AZD7442Biological

    Participants are no longer being randomized to this intervention.

  • MP0420Drug

    Participants are no longer being randomized to this intervention.

  • PF-07304814Drug

    250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from randomization to sustained recoveryTime frame: Up to Day 90

Locations

135 sites in 10 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue

    Tucson, Arizona

  • Southern Arizona VA Healthcare System (Site 074-009), 3601 S. 6th Ave.

    Tucson, Arizona

  • Velocity Chula Vista (Site 080-034), 752 Medical Center Ct., Ste. 304

    Chula Vista, California

  • Community Regional Medical Center (Site 203-005), 2823 Fresno Street

    Fresno, California

  • Velocity San Diego (Site 080-035), 5565 Grossmont Center Drive, Building 2, Suite 1

    La Mesa, California

  • VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street

    Loma Linda, California

  • VA Long Beach Healthcare System (Site 074-026), 5901 East 7th Street (09/151-M2)

    Long Beach, California

  • Keck Hospital of USC (Site 301-020), 1500 San Pablo Street

    Los Angeles, California

  • Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd.

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza

    Los Angeles, California

  • Sacramento VA Medical Center (Site 074-023), 10535 Hospital Way

    Mather, California

  • Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive

    Newport Beach, California

  • Palo Alto VAMC (Site 074-005), 3801 Miranda Avenue

    Palo Alto, California

  • UC Davis Health (Site 203-004), 2315 Stockton Blvd.

    Sacramento, California

  • VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive

    San Diego, California

  • UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St.

    San Francisco, California

  • San Francisco VAMC (Site 074-002), 4150 Clement St.

    San Francisco, California

  • UCSF Medical Center (Site 203-001), Moffitt-Long Hospital, 505 Parnassus Ave.

    San Francisco, California

  • Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr.

    Stanford, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson Street, CDCRC Building

    Torrance, California

  • University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue

    Aurora, Colorado

  • Denver Public Health (Site 017-004), 660 Bannock St., MC2600 (Infectious Disease Clinic)

    Denver, Colorado

  • National Jewish Health / St. Joseph Hospital (Site 204-003), 1400 Jackson Street

    Denver, Colorado

  • West Haven VA Medical Center (Site 025-007), 950 Campbell Avenue

    West Haven, Connecticut

  • MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW

    Washington D.C., District of Columbia

  • MedStar Health Research Institute (Site 009-021), MedStar Washington Hospital Center, 110 Irving St., NW.

    Washington D.C., District of Columbia

  • Washington DC VA Medical Center (Site 009-004), 50 Irving Street NW

    Washington D.C., District of Columbia

  • Bay Pines VAMC (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104

    Bay Pines, Florida

  • Baycare Health System (Site 301-025), Morton Plant Hospital, 300 Pinellas Street

    Clearwater, Florida

  • North Florida/South Georgia Veterans Health System (Site 074-011), 1601 SW. Archer Road

    Gainesville, Florida

  • Memorial Healthcare System (Site 648-002), Memorial Regional Hospital, 3501 Johnson Street

    Hollywood, Florida

  • Miami VAMC (Site 074-003), 1201 NW 16 Street

    Miami, Florida

  • Hillsborough County Health Department, University of South Florida (Site 032-001)

    Tampa, Florida

  • Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE

    Atlanta, Georgia

  • Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard

    Fort Wayne, Indiana

  • Cotton O'Neil Clinical Research Center (Site 080-030), Stormont Vail Health, 1500 SW 10th Avenue

    Topeka, Kansas

  • University of Kentucky Hospital (Site 210-004), 1000 South Limestone St.

    Lexington, Kentucky

  • Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway

    New Orleans, Louisiana

  • University of Maryland Medical Center (Site 301-019), 22 South Greene Street

    Baltimore, Maryland

  • Massachusetts General Hospital (Site 202-002), 55 Fruit Street

    Boston, Massachusetts

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.